METHOD FOR TARGETED TREATING DERMATOSES
Disclosed are methods for localized treatment of a skin condition including administering a therapeutically effective amount of at least one systemic drug to the subject, utilizing a dosimetry device to transmit varying percentages of the UVB light to an area of the subject's skin; assessing a response of the treated area to the varying percentages of the UVB light transmitted thereto; and determining an optimal dose of UVB light, based on the response of the treated area to the varying percentages of UVB light and to the systemic drug; and applying the optimal dose of UVB light to the treatment area.
1 .- 37 . (canceled)
38 . A method for localized treatment of a skin condition, the method comprising the steps of:
a. administering a therapeutically effective amount of at least one systemic drug to the subject;
b. utilizing a dosimetry device, comprising an optical matrix comprising a plurality of regions, each region configured to allow varying percentages of UVB light to pass therethrough, to transmit varying percentages of the UVB light to an area of the subject's skin;
c. assessing a response of the treated area to the varying percentages of the UVB light transmitted thereto;
d. determining an optimal dose of UVB light, based on the response of the treated area to the varying percentages of UVB light and the systemic drug administered; and
e. applying the optimal dose of UVB light to the treatment area.
39 . The method of claim 38 , wherein the optimal dose of UVB light is the maximum tolerable dose of UVB light and wherein the method further comprises determining an optimal amount of the systemic drug based on the determined maximum tolerable dose of UVB light.
40 . The method of claim 38 , wherein the transmission of light passing through the regions ranges from about 20% in one region up to about 100% in another region.
41 . The method of claim 38 , wherein the UVB light is UVB laser light having a wavelength of about 290-320 nm.
42 . The method of claim 38 , wherein the UVB light is UVB laser light having a wavelength of about 308 nm and an intensity of 60 mwatts.
43 . The method of claim 38 , wherein the administering of the systemic drug and the applying of the maximum tolerable dose of UVB light is repeated 1-5 times a week.
44 . The method of claim 38 , wherein the administering of the therapeutically effective amount of the at least one systemic drug is initiated at least 2 days prior to the transmitting of the varying percentages of UVB light to a treatment area and the assessment of the response of the treated area to the varying percentages of the UVB light transmitted thereto.
45 . The method of claim 38 , wherein the at least one systemic drug is selected from the group consisting of: Methotrexate, Acitretin, Isotretinoin, Tegison, Cyclosporine, Apremilast, any pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate (e.g., hydrate) or clathrate thereof and combinations thereof.
46 . The method of claim 45 , wherein the at least one systemic drug is Apremilast, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate (e.g., hydrate) or clathrate thereof.
47 . The method of claim 46 , wherein the subject is administered about 10 mg/day to about 20 mg/day of the Apremilast, or the pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate (e.g., hydrate) or clathrate thereof.
48 . The method of claim 38 , wherein the skin condition is selected from vitiligo, psoriasis, leukoderma, atopic dermatitis, dyshidrosis, eczema, alopecia areata and lichen planus.
49 . The method of claim 48 , wherein the skin condition is vitiligo or psoriasis.
50 . A method for localized treatment of a skin condition, the method comprising the steps of:
a. utilizing a dosimetry device, comprising an optical matrix comprising a plurality of regions, each region configured to allow varying percentages of UVB light to pass therethrough, to transmit varying percentages of the UVB light to an area of the subject's skin affected with the skin condition;
b. assessing a response of the skin area to the varying percentages of the UVB light transmitted thereto;
c. determining an optimal dose of UVB light, based on the response of the treated skin area to the varying percentages of UVB light;
d. determining an optimal dose of at least one systemic drug, based on the determined optimal dose of UVB light;
e. administering the optimal dose of the systemic drug to the subject, and
f. treating the skin area with the optimal dose of UVB light.
51 . The method of claim 50 , wherein the optimal dose of UVB light is the maximum tolerable dose of UVB light.
52 . The method of claim 50 , wherein the transmission of light passing through the regions ranges from about 20% in one region up to about 100% in another region.
53 . The method of claim 50 , wherein the UVB light is UVB laser light having a wavelength of about 290-320 nm.
54 . The method of claim 50 , wherein the UVB light is UVB laser light having a wavelength of about 308 nm and an intensity of 60 mwatts.
55 . The method of claim 50 , wherein the treatment area is assessed approximately 24 to 48 hours after the varying percentages of the UVB light are applied thereto.
56 . The method of claim 50 , wherein the at least one systemic drug is Apremilast, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate (e.g., hydrate) or clathrate thereof.
57 . The method of claim 50 , wherein the skin condition is selected from vitiligo, psoriasis, leukoderma, atopic dermatitis, dyshidrosis, eczema, alopecia areata and lichen planus.
58 . The method of claim 57 , wherein the skin condition is vitiligo or psoriasis.